anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: To provide an amino acid-type glycolipid having a specific structure and high hydrophobic property, stably introducible into the bimolecular membrane of a phospholipid microsome and, accordingly, useful as a microsome-stabilizing agent having excellent performance and economy and synthesizable in a mass at a low cost. CONSTITUTION: This lipid contains an amino group of an amino acid bonded to the anomer site of a terminal aldose of a sugar having a sugar unit number of 2-50 and two hydrophobic groups introduced into the amino group or the carboxylic acid group of the amino acid. The sugar to be used as a raw material is preferably an oligosaccharide having aldose on the sugar chain terminal and having a sugar unit number of 5-20. The amino acid is preferably glutamic acid, etc.  The above lipid can be produced e.g. by successively converting the sugar chain terminal aldose to carboxylic acid salt and proton, forming a lactone, bonding the lactone group through an amide bond to the amino group of an amino acid after converting the carboxylic acid part of the amino acid into a tetraalkylammonium salt and reacting the product with an alkyl halide to introduce a hydrophobic group such as alkyl group into the carboxylic acid group of the amino acid.
BACKGROUND: Coronary microvascular dysfunction (CMD) is frequently observed in atrial fibrillation (AF), the most commonly sustained arrhythmia. Nevertheless, an in-depth prognostic significance of CMD in AF is lacking. We aimed to provide insight into the predictive impact of CMD assessed by a novel non-invasive coronary angiography-derived index of microcirculatory resistance (caIMR) for major adverse events (MACE) in AF patients.
METHOD: This study included patients with AF who underwent invasive coronary angiography due to suspected cardiac ischemia and did not exhibit obstructive epicardial coronary artery disease (≤50 % stenosis). The caIMR was prospectively evaluated, and the optimal cutoff value for predicting MACE was determined through ROC analysis.
RESULT: A total of 463 patients with AF were enrolled. During a median of 33 months of follow-up, 111 (23.97 %) patients had MACE endpoints. The best caIMR cutoff value was 39.28. In patients with MACE, both the mean caIMR and the prevalence of elevated caIMR (caIMR>39.28) were significantly higher compared to those without MACE. An elevated caIMR was linked to a higher risk of MACE (log-rank P < 0.001) and emerged as an independent predictor of clinical outcomes (HR: 4.029; 95 % CI: 2.529-6.418; P < 0.001). In addition, the risk of MACE was higher in high caIMR patients with non-paroxysmal AF (log-rank P < 0.001) and no catheter ablation (log-rank P < 0.001).
CONCLUSION: Elevated caIMR is common and showed a vital independent prognostic significance in AF patients. In addition to well-known risk factors, assessment of microvascular function can be a feasible approach for early prevention and a therapeutic target in AF patients.
A device for delivery of copper to the skin for therapeutic effect. A flexible patch is formed of a matrix material embedded or intermixed with copper particles. The matrix material is selected for its compatibility with the human skin. The patch is held in a conforming manner by a sleeve or other means to retain the patch against a targeted skin area. A contact area of the patch contains at least a portion of the copper particles, the surfaces of which are put in contact with the skin. Silicone is a preferred matrix material. The invention includes elastic braces including a copper containing patch and designed for encompassing a knee, wrist or other portion of the body.
A Japanese man in his 20s was referred to our hospital with a two-month history of abdominal fullness and leg edema. Abdominal computed tomography revealing massive ascites and ostial blockage of the main hepatic veins, and angiographic evaluation demonstrating obstruction of the main hepatic veins yielded a diagnosis of Budd-Chiari syndrome (BCS). Diuretic agents were prescribed for the ascites but failed to provide relief. The patient was referred to our department for further evaluation and treatment. Angiography showed ostial obstruction of the main hepatic veins, with most of the portal hepatic flow draining from an inferior right hepatic vein (IRHV) into the inferior vena cava (IVC) thorough an intrahepatic portal venous and venovenous shunt. Access between the main hepatic veins and IVC was impossible, but cannulation between the IRHV and IVC was achieved. Because of the venovenous connection between the main hepatic vein and the IRHV, metallic stents were placed into two IRHVs to decrease congestion in the hepatic venous outflow. After stent placement followed by balloon expansion, the gradient pressure between the hepatic vein and IVC improved remarkably. The ascites and lower leg edema improved postoperatively, and long-term stent patency (6 years) was achieved.
Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most commonly selected measures or their potential sensitivity to detect changes resulting from the interventions being examined. The aim of this systematic review is to assess the frequency and diversity of body composition measures that have been used in cancer cachexia trials. MEDLINE, Embase and Cochrane Library databases were systematically searched between January 1990 and June 2021. Eligible trials examined adults (≥18 years) who had received an intervention aiming to treat or attenuate the effects of cancer cachexia for >14 days. Trials were also of a prospective controlled design and included body weight or at least one anthropometric, bioelectrical or radiological endpoint pertaining to body composition, irrespective of the modality of intervention (e.g., pharmacological, nutritional, physical exercise and behavioural) or comparator. Trials with a sample size of <40 patients were excluded. Data extraction used Covidence software, and reporting followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidance. This review was prospectively registered (PROSPERO: CRD42022276710). A total of 84 clinical trials, comprising 13 016 patients, were eligible for inclusion. Non-small-cell lung cancer and pancreatic cancer were studied most frequently. The majority of trial interventions were pharmacological (52%) or nutritional (34%) in nature. The most frequently reported endpoints were assessments of body weight (68 trials, n = 11 561) followed by bioimpedance analysis (BIA)-based estimates (23 trials, n = 3140). Sixteen trials (n = 3052) included dual-energy X-ray absorptiometry (DEXA)-based endpoints, and computed tomography (CT) body composition was included in eight trials (n = 841). Discrepancies were evident when comparing the efficacy of interventions using BIA-based estimates of lean tissue mass against radiological assessment modalities. Body weight, BIA and DEXA-based endpoints have been most frequently used in cancer cachexia trials. Although the optimal endpoints cannot be determined from this review, body weight, alongside measurements from radiological body composition analysis, would seem appropriate. The choice of radiological modality is likely to be dependent on the trial setting, population and intervention in question. CT and magnetic resonance imaging, which have the ability to accurately discriminate tissue types, are likely to be more sensitive and provide greater detail. Endpoints are of particular importance when aligned with the intervention's mechanism of action and/or intended patient benefit.
Participants randomized to the intervention group will be allocated a pre-registered Inspire II model Fitbit. The kinesiologist will design a personalized exercise prescription for the participant. The kinesiologist will follow up with the participants every 2 weeks for 3 months to discuss their progress and to modify or advance their exercise prescriptions as needed.
The invention relates to amygdalus communis l seed lung moisturizing and cough stopping bath powder and a production method thereof. The amygdalus communis l seed lung moisturizing and cough stopping bath powder comprises a drug powder bag and a perfume bag, wherein the drug powder bag is prepared from the following raw materials by weight: 35-45 parts of amygdalus communis l seed l, 10-16 parts of leymus secalinus (georgi) tzvel, 10-16 parts of herb of ludisia discolor (ker-gawl.) a. rich, 5-8 parts of lindernia angustifolia(benth.), 5-8 parts of clinopodium chinense (benth.) o. ktze, 5-8 parts of laportea sinensis c.h.wright, 5-8 parts of nothosmyrnium japonicum var. sutchuensis, 3-6 parts of freshwater sponge, 3-6 parts of blainvillea acmell. (l.) philipson, 3-6 parts of amischotolype hispida, and 3-6 parts of root of oriental paperbush, and the perfume bag is prepared from the following raw materials by weight: 10-12 parts of rose, 8-10 parts of rosa chinensis, 6-8 parts of citrus aurantium l, 3-5 parts of lilac, and 3-5 parts of lavender. The main steps of the production method comprise that (1) the drug powder bag production steps comprise: A, raw material pre-treatment, B, soaking, evaporation to achieve a dried state, chopping, and baking-frying, C, filtration liquid extracting, D, centrifugal separation and solution mixing, and E, concentration and drying; (2) a perfume bag is produced; and (3) the drug powder bag and the perfume bag are packaged into a packaging bag so as to prepare the finished product. According to the present invention, after the amygdalus communis l seed lung moisturizing and cough stopping bath powder is used for a long time, the effects of lung moisturizing, cough stopping, heat clearing, phlegm dissipating, asthma relieving and qi descending can be provided.
A computer assisted programming method includes ramping up a stimulation current for a plurality of contacts on a lead. Patient feedback is received while the stimulation current is being ramped up. Patient feedback indicates that the patient is beginning to feel stimulation. Based on the patient feedback, amplitude of the stimulation current that resulted in the patient feedback is recorded, and contacts are divided into groups. The contacts are activated one group at a time to the recorded amplitude. For each activated group of contacts, whether the patient can feel stimulation is determined. Thereafter, the target group that caused the patient to feel stimulation is then sub-divided into sub-groups. This process repeats a plurality of cycles until one or more contacts that caused the patient to feel stimulation are identified. The recorded amplitude is assigned as a perception threshold for the identified one or more contacts.
The present invention relates to a peel-off type military camouflage cream pack, comprising ′polyvinyl alcohol′ as a film forming component, and to a production method of a composition, which can be easily removed compared to existing camouflage creams. Unlike existing camouflage creams, the present invention is easy to remove simply and cleanly by a peel-off method after being applied to the face and solidifying a liquid cream. The camouflage cream pack of the present invention is produced by blending: 15 to 25 parts by weight of green - a green tea extract and an aloe extract, black - a charcoal extract, brown - a red ginseng extract and a mud extract according to each color; 15 to 25 parts by weight of collagen; 15 to 25 parts by weight of a UV-blocking ingredient formulated with titanium dioxide and zinc oxide; 15 to 25 parts by weight of essence; and 15 to 25 parts by weight of polyvinyl alcohol and polyvinylpyrrolidone in the same ratio. First, there is each tube-type camouflage cream when a top cover is opened. A lid of the tube-type camouflage cream is opened, and a gel-type camouflage cream according to each purpose is applied. While the face is checked through a mirror attached to the inside of the lid, and the same is applied.
Novel antimicrobial peptides from bovine and murine neutrophils are provided.  The peptides, designated bovine granulocyte peptide A (BGP-A) and murine granulocyte peptide A (MGP-A) were purified to homogeneity from peripheral blood granulocytes. The amino acid and nucleotide sequence of BGP-A and MGP-A  are also provided. A synthetic version of BGP-A and MGP-A is also provided.  The purified BGP-A peptide is shown to have antimicrobial activity indistinguishable from that of natural BGP-A. Synthetic carboxamidated analogs of BGP-A (BGP-A-amide) and MGP-A (MGP-A-amide) are also provided.
Active substance combination (A) comprises (a) at least one substituted carbinol compound (I), optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or its salt or solvate, and (b) at least one opioid. Active substance combination (A) comprises (a) at least one substituted carbinol compound of formula (I), optionally in the form of one of its stereoisomers, preferably enantiomers or diastereomers, its racemate or in the form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or its salt or solvate, and (b) at least one opioid. R 1>H, alkyl, alkenyl, an optionally at least mono-substituted cycloaliphatic radical (which may contain at least one N atom as ring member) or phenyl; R 2>H, an optionally at least one N-atom as ring member containing cycloaliphatic radical (which may be at least monosubstituted by alkyl and/or alkylene), NR 3>R 4>-moiety or NR 5>R 6>-moiety (both which is bound via alkylene group); R 3>, R 4>alkyl or benzyl radical; NR 5>R 6>saturated optionally at least one further heteroatom as ring member containing heterocyclic radical; X : optionally at least mono-substituted phenyl radical or optionally at least mono-substituted thienyl radical (where each case the substituents optionally alkyl, alkoxy or which is at least partially halogenated or halo atom); and Y : heteroaryl (which contains one or more N-atoms as ring members and which is unsubstituted or at least mono-substituted by one or more substituents of CN group, carboxy bound, methoxy carbonyl group, OH, NH 2, 1-4C dialkylamino group (all bound via 1-4C alkylene group), halo, alkyl, benzyl or cycloaliphatic radical (which contains at least one nitrogen atom as ring member and which is bound via 1-4C alkylene group)) or unsubstituted heteroaryl radical (which contains two nitrogen atoms as ring members and which is condensed with a saturated, one methyl-substituted nitrogen atom as ring member containing cycloaliphatic group). An independent claim is also included for a composition (B) comprising (A) and at least one further active substance and/or an auxiliary substance. [Image] ACTIVITY : Analgesic; Antimigraine; Uropathic; Neuroprotective; Antiinflammatory. MECHANISM OF ACTION : None given.
Family caregivers are at high risk of psychological distress and low sleep efficiency resulting from their caregiving responsibilities. Although psychological symptoms are associated with sleep efficiency, there is limited knowledge about the association of psychological distress with variations in sleep efficiency. We aimed to characterize the short- and long-term patterns of caregivers' sleep efficiency using Markov chain models and compare these patterns between groups with high and low psychological symptoms (i.e., depression, anxiety, and caregiving stress). Based on 7-day actigraphy data from 33 caregivers, we categorized sleep efficiency into three states, < 75% (S1), 75-84% (S2), and ≥ 85% (S3), and developed Markov chain models. Caregivers were likely to maintain a consistent sleep efficiency state from one night to the next without returning efficiently to a normal state. On average, it took 3.6-5.1 days to return to a night of normal sleep efficiency (S3) from lower states, and the long-term probability of achieving normal sleep was 42%. We observed lower probabilities of transitioning to or remaining in a normal sleep efficiency state (S3) in the high depression and anxiety groups compared to the low symptom groups. The differences in the time required to return to a normal state were inconsistent by symptom levels. The long-term probability of achieving normal sleep efficiency was significantly lower for caregivers with high depression and anxiety compared to the low symptom groups. Caregivers' sleep efficiency appears to remain relatively consistent over time and does not show rapid recovery. Caregivers with higher levels of depression and anxiety may be more vulnerable to sustained suboptimal sleep efficiency.
Infants with type 1 ROP and no prior treatment for ROP will be randomly assigned (1:1) to treatment with either intravitreous bevacizumab 0.063 mg or peripheral retinal laser ablation. Study exams will be at weeks 1, 2, and 4 weeks, and at 2 and 4-months post-treatment (and re-treatment when indicated). Additional study exams will occur at adjusted age 6 months, 1 year, and then annually for 5 more years. Non-study examinations will be at clinician discretion and are likely to occur more often. The primary outcome will be treatment success, defined as no worsening of ROP 5-13 days after treatment (or re-treatment if indicated), no plus disease or severe neovascularization 2 weeks to 6 months after treatment (or re-treatment if indicated), and no unfavorable structural outcome (or prior scleral buckle or vitrectomy) at 6 months adjusted age. Important secondary outcomes include the number of re-treatments, extent of retinal vascularization, refractive error, neurodevelopment assessed by the Bayley-4 test, IQ and neuropsychiatric testing, visual acuity, visual fields, and systemic morbidities.
Patients receive oral cediranib maleate once daily in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment with paclitaxel and carboplatin repeats every 21 days for 6-8 courses in the absence of disease progression or unacceptable toxicity.
OBJECTIVE: Our goal was to find metabolism-related lncRNAs that were associated with osteoporosis (OP) and construct a model for predicting OP progression using these lncRNAs.
METHODS: The GEO database was employed to obtain gene expression profiles. The WGCNA technique and differential expression analysis were used to identify hypoxia-related lncRNAs. A Lasso regression model was applied to select 25 hypoxia-related genes, from which a classification model was created. Its robust classification performance was confirmed with an area under the ROC curve close to 1, as verified on the validation set. Concurrently, we constructed a ceRNA network based on these genes to unveil potential regulatory processes. Biologically active compounds of STZYD were identified using the Traditional Chinese Medicine System Pharmacology Database and Analysis Platform (TCMSP) database. BATMAN was used to identify its targets, and we obtained OP-related genes from Malacards and DisGeNET, followed by identifying intersection genes with metabolism-related genes. A pharmacological network was then constructed based on the intersecting genes. The pharmacological network was further integrated with the ceRNA network, resulting in the creation of a comprehensive network that encompasses herb-active components, pathways, lncRNAs, miRNAs, and targets. Expression levels of hypoxia-related lncRNAs in mononuclear cells isolated from peripheral blood of OP and normal patients were subsequently validated using quantitative real-time PCR (qRT-PCR). Protein levels of RUNX2 were determined through a western blot assay.
RESULTS: CBFB, GLO1, NFKB2 and PIK3CA were identified as central therapeutic targets, and ADD3-AS1, DTX2P1-UPK3BP1-PMS2P11, TTTY1B, ZNNT1 and LINC00623 were identified as core lncRNAs.
CONCLUSIONS: Our work uncovers a possible therapeutic mechanism for STZYD, providing a potential therapeutic target for OP. In addition, a prediction model of metabolism-related lncRNAs of OP progression was constructed to provide a reference for the diagnosis of OP patients.
The present invention is a cosmetic composition comprising a polymer which is an addition polymer of a (meth) acrylic grafted silicone as a polymeric crosslinking agent and an organohydrogen polysiloxane represented by general formula (4), wherein the (meth) acrylic grafted silicone has a main chain having a repeating unit of a (meth) acrylic group represented by formulae (I), (II) and (III), and has an unsaturated bond and an organopolysiloxane structure in a side chain. By blending a polymer having high affinity with a liquid oil, a cosmetic excellent in storage stability and use feeling can be provided. A is a group selected from an alkoxy group having 1 to 22 carbon atoms and an aryloxy group having 6 to 20 carbon atoms. B is represented by formula (1)Unsaturated bond groups. C is a group represented by formula (2) or a group represented by formula (3-1) or (3-2). M  x  D  y  T  z  Q  w  (4)。
The placebo has the same nutrient composition (e.g. 13 grams of sucrose and 6.44 grams of casein) as the active and will be equicaloric, and will also be mixed with a shot of sterile water (80 ml). The main difference of the placebo is that this nutrient mixture will be immediately released in the stomach, instead of being delivered to the ileum (active). This immediate release of the nutrient mixture is possible by using a different micro-encapsulation technique.
BACKGROUND: Heart failure (HF) is a serious condition with increasing prevalence, high morbidity, and increased mortality. Obesity is an established risk factor for HF. Fluctuation in body mass index (BMI) has shown a higher risk of cardiovascular outcomes. We investigated the association between BMI variability and incident HF.
METHODS AND RESULTS: In the UK Biobank, we established a prospective cohort after excluding participants with prevalent HF or cancer at enrollment. A total of 99 368 White participants with ≥3 BMI measures during >2 years preceding enrollment were included, with a median follow-up of 12.5 years. The within-participant variability of BMI was evaluated using standardized SD and coefficient of variation. The association of BMI variability with incident HF was assessed using Fine and Gray's competing risk model, adjusting for confounding factors and participant-specific rate of BMI change. Higher BMI variability measured in both SD and coefficient of variation was significantly associated with higher risk in HF incidence (SD: hazard ratio [HR], 1.05 [95% CI, 1.03-1.08], P<0.0001; coefficient of variation: HR, 1.07 [95% CI, 1.04-1.10], P<0.0001).
CONCLUSIONS: Longitudinal health records capture BMI fluctuation, which independently predicts HF incidence.
Kaleidoscope includes shapes of flowers and mirrors in the shape of triangle placed with an angle of 600. While rotating one of the cylinders, various shapes and colourful eyes are formed when viewed with one eye. When the kaleidoscope is rotated, the patterns look different all the time because the colourful parts are moving, attracting the child's attention.